论文部分内容阅读
目的:观察血清超敏C反应蛋白(HSCRP)在慢性阻塞性肺病(COPD)急性加重期和治疗稳定后的浓度变化,探讨血清HSCRP检测在慢性阻塞性肺病急性加重期的临床意义。方法:应用免疫透射比浊法对98例COPD急性加重期患者在入院治疗前和治疗病情缓解后进行血清HSCRP浓度检测并与40例正常对照组进行比较。结果:COPD急性加重期患者在入院治疗前、治疗病情缓解后及正常对照组HSCRP水平分别为48.74±7.5、2.12±0.42和0.64±0.05(ug/ml),COPD急性加重期患者HSCRP水平明显高于正常对照组,差异具有统计学意义(P<0.01),治疗稳定后HSCRP浓度与正常对照组相比,差异无统计学意义。结论:HSCRP检测可作为COPD急性加重期的诊断及严重度评估的一个灵敏指标。
OBJECTIVE: To observe the change of serum concentration of HSCRP after acute exacerbation and stable treatment of chronic obstructive pulmonary disease (COPD), and to explore the clinical significance of serum HSCRP detection in acute exacerbation of chronic obstructive pulmonary disease. Methods: 98 cases of acute exacerbation of COPD were detected by immunoturbidimetry before treatment and after remission of treatment. Serum HSCRP levels were measured and compared with 40 normal controls. Results: The levels of HSCRP in patients with acute exacerbation of COPD were 48.74 ± 7.5, 2.12 ± 0.42 and 0.64 ± 0.05 (ug / ml), respectively, before and after treatment. The levels of HSCRP in patients with acute exacerbation of COPD were significantly higher In the normal control group, the difference was statistically significant (P <0.01). After treatment, the HSCRP concentration was not significantly different from the normal control group. Conclusion: HSCRP can be used as a sensitive indicator in the diagnosis and severity of acute exacerbation of COPD.